Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 193 900 KRW 0.73% Market Closed
Market Cap: 40.2T KRW
Have any thoughts about
Celltrion Inc?
Write Note

P/E
Price to Earnings

214.7
Current
43.5
Median
22.1
Industry
Higher than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
214.7
=
Market Cap
40.2T KRW
/
Net Income
187.1B KRW
All Countries
Close
Market Cap P/E
KR
Celltrion Inc
KRX:068270
40.2T KRW 214.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -180 740.1
US
Abbvie Inc
NYSE:ABBV
310.3B USD 61.1
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 33.5
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 915.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD -213.4
US
Epizyme Inc
F:EPE
94.1B EUR -472.7
AU
CSL Ltd
ASX:CSL
134.4B AUD 31.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 16.6
US
Seagen Inc
F:SGT
39.3B EUR -54.7
NL
argenx SE
XBRU:ARGX
35.8B EUR -134.7
Earnings Growth P/E to Growth
KR
Celltrion Inc
KRX:068270
Average P/E: 212.2
214.7
217%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -134.7 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
74.8
2-Years Forward
P/E
31.7
3-Years Forward
P/E
23.7

See Also

Discover More